
Biotest AG
XETRA:BIO

Intrinsic Value
The intrinsic value of one
BIO
stock under the Base Case scenario is
31.95
EUR.
Compared to the current market price of 42.4 EUR,
Biotest AG
is
Overvalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Biotest AG
Fundamental Analysis


Revenue & Expenses Breakdown
Biotest AG
Balance Sheet Decomposition
Biotest AG
Current Assets | 704.5m |
Cash & Short-Term Investments | 37.8m |
Receivables | 171.8m |
Other Current Assets | 494.9m |
Non-Current Assets | 642.2m |
Long-Term Investments | 26.5m |
PP&E | 573.9m |
Intangibles | 16.4m |
Other Non-Current Assets | 25.4m |
Free Cash Flow Analysis
Biotest AG
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Biotest AG
Revenue
|
707m
EUR
|
Cost of Revenue
|
-467m
EUR
|
Gross Profit
|
240m
EUR
|
Operating Expenses
|
-150.8m
EUR
|
Operating Income
|
89.2m
EUR
|
Other Expenses
|
-20.7m
EUR
|
Net Income
|
68.5m
EUR
|
BIO Profitability Score
Profitability Due Diligence
Biotest AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Score
Biotest AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
BIO Solvency Score
Solvency Due Diligence
Biotest AG's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Score
Biotest AG's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIO Price Targets Summary
Biotest AG
Dividends
Current shareholder yield for BIO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BIO
stock under the Base Case scenario is
31.95
EUR.
Compared to the current market price of 42.4 EUR,
Biotest AG
is
Overvalued by 25%.